Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03156361
Other study ID # DP 01-2017-02
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 18, 2017
Est. completion date March 15, 2018

Study information

Verified date April 2017
Source Diasome Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Single Center, Double Blind, Active Comparator Controlled 2-Way Crossover Multiple Dose Safety, Tolerability and Efficacy Study


Description:

This is a single center, double blind, active comparator controlled 2-Way crossover multiple dose safety, tolerability and efficacy study.

The study will consist of three periods. Total duration will be approximately nine weeks, including a screening period of up to 14 days, a 7-day run-in period and two 21-day treatment periods.

Subjects will be screened and then they will undergo a week of baseline CGM. They will then be randomized to one of two treatment sequences: three weeks of treatment with HDV-lispro followed by three weeks of treatment with insulin lispro diluted with sterile water to match the insulin concentration in HDV-lispro, or the same treatments in the reverse order.

A test meal study (standardized liquid test meal) is to be conducted at the beginning of treatment (baseline study) and at the end of each three week treatment period. As noted above, frequent blood samples will be collected for glucose and insulin levels during the first (baseline study) test meal; during the two test meals performed after the two treatment periods the same sampling for glucose and insulin will be performed, with the addition of collecting samples for glucagon levels.

Subjects will also perform blinded continuous glucose monitoring throughout the entirety of the study (7 weeks).

Throughout study, subjects will be asked to perform frequent self-monitoring of blood glucose (SMBG), at least 6 times per day (before and 60-90 minutes after each meal) during 3 or more days of each week. This will serve as data for therapeutic decision-making as well as for data collection.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date March 15, 2018
Est. primary completion date January 15, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. T1DM =12 months

2. C-peptide <0.6 ng/mL (a single re-test is allowable)

3. Treatment with rapid analog insulin by CSII for the previous 6 months

4. Familiarity with continuous glucose monitoring (CGM) technology; subjects nee d not be currently using CGM but should have used it in the past. Personal (unblinded) CGM will NOT be allowed during the study

5. Willingness to use insulin lispro as the analog insulin during the study period

6. Use of MiniMed Paradigm® pump for the previous 6 months. Pumps that employ low glucose suspend technology will NOT be allowed during the study

7. BMI =18.0 kg/m2 and =35.0 kg/m2

8. A1C=9.0% (a single re-test is allowable)

Exclusion Criteria:

1. Known or suspected allergy to any component of any of the study drugs in this trial.

2. A patient who has unstable proliferative retinopathy or maculopathy, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator.

3. Use of oral anti-diabetic or non-insulin anti-diabetic injection therapies (e.g. SGLT-2 inhibitors, pramlintide, GLP-1 agonists, etc.)

4. Current smokers; if a former smoker, no tobacco products (inhaled, oral or buccal) for the previous 3 months

5. As judged by the investigator, clinically significant active disease of the gastrointestinal, cardiovascular (including a history of arrhythmia or conduction delays on ECG), hepatic, neurological, renal, genitourinary, or hematological systems, or uncontrolled hypertension (diastolic blood pressure = 100 mmHg and/or systolic blood pressure = 160 mmHg after 5 minutes in the supine position).

6. History of any illness or disease that in the opinion of the Investigator might confound the results of the trial or pose additional risk in administering the study drugs to the patient.

Study Design


Intervention

Drug:
HDV insulin lispro 100 UNIT/mL
Hepatic Directed Vesicle (HDV) added to commercial insulin lispro
Insulin Lispro 100 Units/mL
Sterile Water for Injection added to commercial insulin lispro

Locations

Country Name City State
United States Atlanta Diabetes Association Atlanta Georgia

Sponsors (2)

Lead Sponsor Collaborator
Diasome Pharmaceuticals Integrium

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glucose area under the curve To evaluate glucose response (incremental AUC) to standardized test meal challenge following 21 days of CSII treatment with HDV insulin lispro versus insulin lispro diluted with sterile water 21 days
Secondary total units Insulin To compare insulin doses (basal, bolus and total) during HDV insulin lispro treatment 21 days
See also
  Status Clinical Trial Phase
Completed NCT03623113 - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes N/A
Withdrawn NCT03396484 - Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes Phase 2
Completed NCT03117998 - Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus Phase 2
Recruiting NCT03369821 - EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)
Completed NCT03202732 - DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes N/A
Completed NCT03704818 - Dapagliflozin Effects on Hypoglycemia Phase 1
Recruiting NCT03864991 - Lifestyle Changes and Glycemic Control in T1D N/A
Completed NCT03725657 - Correlation Between Exercise and Insulin Dose in a Camp for Pediatric Type 1 Patients
Completed NCT02985866 - The International Diabetes Closed Loop (iDCL) Trial: Protocol 1 N/A
Completed NCT03003806 - Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro Study N/A
Withdrawn NCT04147637 - FreeStyle Libre Plus Bluetooth Transmitter Adjunct: Can This Improve Glucose Accuracy and Reduce Burden of Hypoglycaemia N/A
Completed NCT03970889 - Real-time Reminders To Decrease Late or Missed Meal Boluses N/A
Recruiting NCT04589325 - Ixekizumab Diabetes Intervention Trial (I-DIT) Phase 2
Completed NCT03367390 - A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM) Phase 1
Completed NCT03738852 - Mechanisms for Restoration of Hypoglycemia Awareness Early Phase 1
Completed NCT03406585 - Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes Phase 1/Phase 2
Completed NCT03859856 - Ovarian Reserve in Diabetes Mellitus
Withdrawn NCT04102202 - BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Phase 1/Phase 2
Terminated NCT03353792 - Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients N/A
Recruiting NCT03811470 - China Diabetes Registry by Metabolic Management Center